Literature DB >> 9612679

Incontinence after surgery for benign prostatic hypertrophy: the case for complex approach and treatment.

C Theodorou1, G Moutzouris, D Floratos, D Plastiras, C Katsifotis, N Mertziotis.   

Abstract

OBJECTIVE: Whether incontinence after surgery for benign prostatic hypertrophy (BPH) requires simple workup and treatment or being a more complex condition and multifactorial in etiology requiring combined surgical techniques should be investigated in more detail.
METHODS: We retrospectively reviewed the records of 56 patients referred to us for post-prostatectomy incontinence after surgery for BPH. All patients were subjected to urodynamics. Twenty-three (41.1%) patients required additional ascending urethrogram and/or cystourethroscopy, according to their associated symptomatology and the urodynamic findings, for a definitive diagnosis to be established.
RESULTS: Twenty-four patients (42.8%) were found to have complex incontinence (either mixed or any type associated with bladder outlet stenosis), requiring combined treatment. Twenty-three (41.1%) had a simple type of incontinence, i.e., pure sphincter incompetence or unstable detrusor. Three patients had residual adenoma and 1 urethral stricture, while 5 patients (8.9%) remained unclassified. Thirty-seven patients were subjected to treatment, 27 (73%) of them to single-modality treatment (artificial urinary sphincter insertion, oxybutynin chloride, transurethral prostatectomy, optical urethrotomy) and the other 10 (27%) to combined treatment (artificial urinary sphincter insertion plus urethroplasty, ileocystoplasty, permanent urethral stent implantation etc.). The overall socially acceptable continence rate (cured plus significantly improved) of the patients subjected to artificial urinary sphincter insertion reached 85%, being better (90%) for the uncomplicated sphincter incompetence group.
CONCLUSIONS: Incontinence after surgery for BPH represents a condition that requires careful evaluation. In a significant proportion of patients, a combination of prosthetic and reconstructive techniques is needed for an optimal result to be achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9612679     DOI: 10.1159/000019618

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.

Authors:  S E Jones; L M Shuba; P Zhabyeyev; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Reconstructive Management Options of Delayed Complications Following Bladder Outlet Surgery.

Authors:  Nora Baker; Carmen Tong; Jay Simhan
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

3.  Artificial urinary sphincter longevity following transurethral resection of the prostate in the setting of prostate cancer.

Authors:  Andrew J Cohen; William Boysen; Kristine Kuchta; Sarah Faris; Jaclyn Milose
Journal:  World J Urol       Date:  2019-03-02       Impact factor: 4.226

4.  Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy.

Authors:  Dionisios Mitropoulos; Stefanos Papadoukakis; Anastasios Zervas; Christos Alamanis; Aris Giannopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  Comparison between Two Different Two-Stage Transperineal Approaches to Treat Urethral Strictures or Bladder Neck Contracture Associated with Severe Urinary Incontinence that Occurred after Pelvic Surgery: Report of Our Experience.

Authors:  A Simonato; M Ennas; A Benelli; A Gregori; F Oneto; E Daglio; P Traverso; G Carmignani
Journal:  Adv Urol       Date:  2012-04-24

6.  Predictive risk factors of postoperative urinary incontinence following holmium laser enucleation of the prostate during the initial learning period.

Authors:  Shuichiro Kobayashi; Masataka Yano; Takayuki Nakayama; Satoshi Kitahara
Journal:  Int Braz J Urol       Date:  2016 Jul-Aug       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.